GLP-1 receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
In 2004, development of an antisense therapy for spinal muscular atrophy began. Over the following years, an antisense oligonucleotide later named nusinersen was developed by Ionis Pharmaceuticals under a licensing agreement with Biogen. In December 2016, nusinersen received regulatory approval from FDA and soon after, from other regulatory agencies worldwide. As of 2020, more than 50 antisense oligonucleotides were in clinical trials, including over 25 in advanced clinical trials (phase II or III). A follow-on drug to Inotersen is being developed by Ionis Pharmaceuticals and under license to Akcea Therapeutics for hereditary transthyretin-mediated amyloidosis. In this formulation the ASO is conjugated to N-Acetylgalactosamine enabling hepatocyte-specific delivery, greatly reducing dose requirements and side effect profile while increasing the level of transthyretin reduction in patients.
Enriched uranium was first manufactured in the early 1940s when the United States and the United Kingdom began their nuclear weapons programs. Later in the decade, France and the Soviet Union began their nuclear weapons and nuclear power programs. Depleted uranium was originally stored as an unusable waste product (uranium hexafluoride) in the hope that improved enrichment processes could extract additional quantities of the fissionable 235U isotope. This re-enrichment recovery of the residual uranium-235 is now in practice in some parts of the world; e.g. in 1996 over 6,000 tonnes (6,600 short tons) were upgraded in a Russian plant. In the 1970s, the Pentagon reported that the Soviet military had developed armor plating for Warsaw Pact tanks that NATO ammunition could not penetrate. The Pentagon began searching for materials to make denser armor-piercing projectiles. After testing various metals, ordnance researchers settled on depleted uranium. The US and NATO militaries used DU penetrator rounds in the 1991 Gulf War, the Bosnia war, bombing of Serbia, the 2003 invasion of Iraq, and 2015 airstrikes on ISIS in Syria. It is estimated that between 315 and 350 short tons (286 and 318 t) of DU were used in the 1991 Gulf War.
The orexinergic projections from the lateral hypothalamus innervate the entirety of the remainder of the hypothalamus, with robust projections to the posterior hypothalamus, tuberomammillary nucleus (the histamine projection nucleus), the arcuate nucleus, and the paraventricular hypothalamic nucleus. In addition to the histaminergic nucleus, the orexin system also projects onto the ventral tegmental area dopamine nucleus, locus ceruleus noradrenergic nucleus, the serotonergic raphe nuclei, and cholinergic pedunculopontine nucleus and laterodorsal tegmental nucleus. The histaminergic, dopaminergic, serotonergic, noradrenergic, and cholinergic nuclei which the lateral hypothalamic orexin neurons project onto constitute the primary components of the ascending reticular activating system. Other output regions include: the ventromedial hypothalamus, medial and lateral septal nuclei, central medial amygdala, zona incerta, periaqueductal gray matter, lateral habenula, diagonal band, substantia innominata (contains the nucleus basalis), stria terminalis, prefrontal cortex, various brain stem substructures, including the rostral ventromedial medulla, rostral ventrolateral medulla, nucleus ambiguus, solitary nucleus, spinal trigeminal nucleus, pontine micturition center, ventral respiratory group, and pontine respiratory group), area postrema, and dorsal nucleus of vagus nerve.
Sources: en.wikipedia.org
== Nomenclature note == Confusingly, there are two nomenclatures for FPR receptors and their genes, the first one used, FPR, FPR1, and FPR2 and its replacement (which corresponds directly to these three respective receptors and their genes), FPR1, FPR2, and FPR3. The latter nomenclature is recommended by the International Union of Basic and Clinical Pharmacology and is used here. Other previously used names for FPR1 are NFPR, and FMLPR; for FPR2 are FPRH1, FPRL1, RFP, LXA4R, ALXR, FPR2/ALX, HM63, FMLPX, and FPR2A; and for FPR3 are FPRH2, FPRL2, and FMLPY.
In 1987, Tengku Razaleigh Hamzah, who had been demoted from Finance Minister to Trade and Industry Minister, challenged Mahathir for UMNO's presidency, and effectively the prime ministership. Razaleigh's bid was supported by Musa, who had resigned as deputy prime minister the previous year. While once close allies with Mahathir, both fell out with Musa claiming that Mahathir no longer trusted him. Razaleigh and Musa ran for the UMNO presidency and deputy presidency on a joint ticket against Mahathir and his new choice for deputy Abdul Ghafar Baba. Mahathir's Team A enjoyed the press's support, most party heavyweights, and even Iskandar, now the Agong. However, other prominent figures such as Abdullah Ahmad Badawi supported Team B. In the election, held on 24 April 1987, Team A prevailed. Mahathir was re-elected by a narrow margin, receiving the votes of 761 party delegates to Razaleigh's 718. Ghafar defeated Musa by a slightly larger margin. Mahathir responded by purging seven Team B supporters from his ministry. At the same time, Team B refused to accept defeat and initiated litigation. In an unexpected decision in February 1988, the High Courts ruled that UMNO was an illegal organisation as some of its branches had not been lawfully registered. Each faction raced to register a new party under the UMNO name. Mahathir's side successfully registered the name "UMNO Baru" ("new UMNO"), while Team B's application to register "UMNO Malaysia" was rejected. Nevertheless, UMNO Malaysia registered the party as Semangat 46 instead under Tengku Razaleigh Hamzah's leadership.
Honokiol is a lignan isolated from the bark, seed cones, and leaves of trees belonging to the genus Magnolia. It has been identified as one of the chemical compounds in some traditional Eastern herbal medicines along with magnolol, 4-O-methylhonokiol, and obovatol. Honokiol, a compound with a spicy odor extracted from various Magnolia species worldwide, including those native to the Southeastern United States and Mexico, can readily cross the blood-brain and cerebrospinal fluid barriers, making it a highly bioavailable and potentially effective therapeutic agent. Honokiol is a small, hydrophobic neolignan biphenol structurally similar to propofol that can be purified efficiently from its isomer magnolol using advanced chromatography techniques such as magnolol acetonide protection followed by flash chromatography or high-capacity high-speed countercurrent chromatography. Extracts from the bark and seed cones of Magnolia trees have been traditionally used in Chinese, Korean, and Japanese medicine as analgesics and treatments for anxiety and mood disorders, notably in formulas like Houpu in Chinese medicine and Kampo in Japan. Honokiol is a pleiotropic natural compound under preliminary research for antitumor, anti-inflammatory, antioxidant, neuroprotective, and antithrombotic properties, showing therapeutic potential across the central nervous system, cardiovascular system, and gastrointestinal system, though it may pose bleeding risks in patients with hemophilia, Von Willebrand disease, or those on anticoagulant therapy.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Mass spectrometry provides a mass value that can be compared with the expected value, while peptide mapping examines fragmentation patterns. Together these techniques support identity claims better than a single measurement can.